Navigation Links
Nile Therapeutics, Inc. Completes $2.5 Million Private Placement
Date:6/23/2011

SAN MATEO, Calif., June 23, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that it has completed its previously announced private placement of units of its securities consisting of an aggregate of 5,000,000 shares of common stock and five-year warrants to purchase an additional 2,500,000 shares of common stock for aggregate gross proceeds of $2.5 million.  

The financing was led by Stonepine Capital, LP. Riverbank Capital Securities, Inc. and Ladenburg Thalmann & Co Inc., each FINRA member broker-dealers, served as placement agents for the transaction.

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and were sold pursuant to Regulation D of the Securities Act.  The securities may not be offered or sold in the United States absent registration under such act and applicable state securities laws or an applicable exemption from those registration requirements. Nile has agreed to file a registration statement covering the resale of the shares issued in the private placement, including the shares issuable upon exercise of the warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Nile Therapeutics

Nile Therapeutics, Inc. is a biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
3. Cell Therapeutics, Inc. Announces Reverse Stock Split
4. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
6. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
8. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
9. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
10. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced that it will hold its 2015 Annual Meeting ... Because the expected date for the Annual ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... BOSTON, MA (PRWEB) December 23, 2014 ... generation webinar series is designed to introduce ... and inform users and partners of platform ... features and benefits; empowering users in their ... and powerful tools. , According to SoundConnect’s ...
(Date:12/24/2014)... December 23, 2014 According to Ross Selinger, ... Affiliate of ITRA Global, the national office market continues to ... This is evidenced by the third quarter’s surprising 3.9% ... Low energy costs have held inflation down and the ... is the housing market remaining soft. , This solid economic ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... Mylan Inc. (Nasdaq: MYL ) today announced ... it holds a 71.2% controlling interest, has been selected ... projects as the primary supplier of five antiretroviral (ARV) ... has been selected as the primary supplier of seven ...
... DIEGO, April 20 Trius Therapeutics, Inc. today announced ... H. Batts, MD, FACP, FIDSA, and G. Ralph Corey, ... group of anti-infective thought leaders. Dr. Batts is ... and the Chief of Infectious Diseases at its ...
... -- Data presented at 100th Annual Meeting of the ... 19 Researchers from Dendreon Corporation (Nasdaq: ... Treatment and Early Cancer Treatment) or P-11 Phase 3 ... responses that are durable and can be maintained following ...
Cached Biology Technology:Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments 2Mylan's Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments 3Trius Appoints Don Batts and Ralph Corey to Clinical Advisory Board 2Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 2Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 3Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 4Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer 5
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... student at Rensselaer Polytechnic Institute has learned very quickly ... medicine go down. In fact, with his invention, the ... most important and complex molecules in the human body, ... communicate with one another. Graduating senior Jeffery Martin has ...
... Mireya Correa, staff scientist at the Smithsonian Tropical Research ... Panama, received the Jos Cuatrecasas Medal for Excellence in ... the National Museum of Natural History and the United ... Botanical Symposium held at the museum. , Jos ...
... gas used as an agricultural pesticide, was introduced in ... and increase fruit yields. Agricultural production nurseries around the ... plants for export and domestic sales. In 2000, the ... and in 2005 MB was banned in the United ...
Cached Biology News:Undergrad has sweet success with invention of artificial Golgi 2Undergrad has sweet success with invention of artificial Golgi 3Smithsonian scientist receives 2008 Medal for Excellence in tropical botany 2Alternatives to ozone-depleting pesticide studied 2
... ,Kit containing Dermal Fibroblasts (Mouse/BalbC) and ... a long-term culture, and is guaranteed to ... growth from the date supplied, when used ... mouse/BalbC, embryonic day 18.5 ,Applications: ...
... QRT-PCR Mixes are formulated for use in ... SYBR Green. One-step QRT-PCR mixes offer a ... The pipetting steps are minimised, making the ... ,The 2x ABsolute QRT-PCR Mix is supplied ...
... are designed for protein pull-down ... sphingosine binding proteins. An order ... of agarose beads with 10 ... the terminus of the alkyl ...
... Immunogen: Synthetic Peptide: M(1) E ... P G P P T M D L ... from mouse cells.,PA1-072 has been successfully used in ... antibody detects an ~86 kDa protein representing Mint3 ...
Biology Products: